In his new position at Reven, Dr. Uckun will provide executive oversight for Reven’s global Research & Development and clinical programs. In addition, Dr. Uckun will contribute medical-scientific leadership and direction for Reven’s basic and translational research activities … Read More
Rejuveinix (RJX) as a drug candidate for patients with systemic inflammatory response syndrome (SIRS): Supportive care considerations for COVID-19, cancer, and sepsis
Sepsis is the consequence of a systemic host inflammatory response to an infection with bacteria, fungi or viruses that is further associated with profound metabolic alterations (1-9). Severe sepsis is frequently associated
with septic shock … Read More
Golden, Colorado, Thursday, June 11, 2020 1:00am MDT – Reven, LLC, a biopharmaceutical company that is developing Rejuveinix (RJX) for patients with cardiovascular and other health conditions, announced today that it recently completed an animal study in connection with its … Read More
Mr. Halverson joins Reven with broad experience in finance, most recently as the Founder, President and Chief Executive Officer of American Sky Financial, a Commercial and Residential Mortgage company serving community banks and developers nationwide. … Read More
Golden, Colorado, Thursday, April 22, 2020 1:00am MDT – Reven, LLC, a biopharmaceutical company that is developing a new drug called Rejuveinix (RJX) for patients suffering cardiovascular and other health conditions, announced today that Michael Volk, Co-Founder, will be stepping … Read More
Golden, Colorado, Friday, April 3, 2020 3:00pm MDT – Reven, LLC, a biopharmaceutical company that is developing its flagship product Rejuveinix (RJX) for patients with vascular and metabolic related health conditions, announced today that it has submitted a proposal to … Read More
A Phase 1, Double-blind, Placebo-controlled, Randomized, Two-Part, Ascending Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Rejuveinix (RJX) in Healthy Participants. Click here for the full study details
Reven successfully completes Phase I clinical trials and is pleased to announce completion with no Serious Adverse Events and no Unexpected Adverse Events. Results are expected to be submitted to the FDA during the next few weeks.
Reven announces Phase II Clinical Development plans for upcoming human efficacy trials. These trials include exploring efficacy as an adjunct therapy for patients suffering Critical Limb Ischemia. Additional areas of focus in separate trials will be for chronic wound healing … Read More
Kevin McGovern Joins Reven’s Board of Directors. Reven announces Kevin McGovern as the newest addition to its Board of Directors. Kevin McGovern Press Release
Reven Hires Dr. James Carlson. Dr. James Carlson hired as Reven’s Executive Vice President of Development Dr. James Carlson Press Release here: Reven Press Release – 011719
MAD Cohort 3 completed dosing on January 15, 2019.
Reven Hires Susan Moore. Susan Moore hired as Reven’s Senior Director of Regulatory and Clinical Affairs.